Celsion Corporation - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLSN Nasdaq 2834 http://celsion.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celsion Corporation

Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress - Oct 15th, 2021 1:00 pm
Celsion Corporation Announces Oral Presentation at International Vaccines Congress - Oct 12th, 2021 1:00 pm
Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews - Oct 11th, 2021 1:00 pm
3 Penny Stocks Insiders Are Buying - Oct 11th, 2021 12:09 pm
CLSN: Initiating Coverage of Celsion Corporation; Novel DNA-Based Cancer Immunotherapy Technology… - Oct 11th, 2021 10:44 am
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities - Oct 5th, 2021 1:00 pm
Celsion to Present at Three Investment Conferences in October - Sep 30th, 2021 1:00 pm
Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine - Sep 17th, 2021 1:00 pm
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies - Sep 3rd, 2021 4:40 pm
Celsion's Vaccine Platform Shows Potential Against COVID-19 In Preclinical Studies - Sep 2nd, 2021 2:02 pm
Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform - Sep 2nd, 2021 12:00 pm
Is Celsion (NASDAQ:CLSN) Using Debt In A Risky Way? - Aug 14th, 2021 9:02 am
Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update - Aug 12th, 2021 12:00 pm
Celsion Corporation to Hold Second Quarter 2021 Financial Results and Business Update Conference Call on Thursday, August 12, 2021 - Aug 5th, 2021 12:00 pm
Results of Celsion’s OVATION 1 Study with GEN-1 in Patients with Advanced Ovarian Cancer Published in the Journal of Clinical Cancer Research - Jul 29th, 2021 2:00 pm
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - Jul 19th, 2021 12:00 pm
Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke - Jul 15th, 2021 12:00 pm
15 Best Penny Stocks to Buy Now - Jul 14th, 2021 1:11 pm
Celsion GmbH Announces Commencement of Enrollment in Oxford University’s Phase 1 Study with ThermoDox® and Focused Ultrasound in Pancreatic Cancer - Jul 1st, 2021 12:00 pm
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox® - Jun 23rd, 2021 12:00 pm